Peptide education
Triptorelin
Triptorelin pamoate · Trelstar · Triptodur
Triptorelin is a prescription GnRH agonist given as an extended-release injection into a muscle. Trelstar is labeled for advanced prostate cancer, and Triptodur is labeled for central precocious puberty (CPP) in children aged two years and older.
Triptorelin treatment depends on the specific depot product, condition, and monitoring plan.
Overview
Quick answer
Trelstar and Triptodur are separate products with different patient populations. Trelstar has three strengths with different release schedules; its label says those strengths are not additive.
What does triptorelin do?
It first stimulates the pituitary hormone pathway. Sustained exposure then suppresses that pathway and lowers sex hormone levels.
What are the Trelstar schedules?
The advanced prostate cancer label describes 3.75 mg every four weeks, 11.25 mg every 12 weeks, or 22.5 mg every 24 weeks, according to the selected formulation.
What is the Triptodur schedule?
The central precocious puberty label describes a 22.5 mg intramuscular injection every 24 weeks for children aged two years and older, with treatment response monitored by the clinical team.
Why is an early hormone rise important?
An initial rise can temporarily worsen prostate cancer symptoms. In children receiving Triptodur, pubertal signs can temporarily increase, including vaginal bleeding.
Evidence
Evidence snapshot
A randomized study compared monthly triptorelin with leuprolide and measured the timing and maintenance of testosterone suppression.
In a single-arm study of 44 children, 41 had a prepubertal stimulated luteinizing hormone (LH) result at month six and maintained suppression through month 12. At month 12, 43 of the 44 children met the LH threshold.
Trelstar and Triptodur have different labeled indications, even where a 22.5 mg strength and 24-week interval appear in both labels.
Claims
Common claims vs evidence
| Claim | Human evidence | Verdict |
|---|---|---|
| Equal milligram amounts make all triptorelin depots interchangeable. | Trelstar and Triptodur have separate labels and indications. The Trelstar label states that its strengths have different release characteristics and are not additive. | Product identity and release schedule matter alongside the stated dose. |
| Monthly triptorelin and leuprolide suppress testosterone at exactly the same speed. | In a randomized study, the percentage reaching the testosterone threshold by day 29 was 91.2% with triptorelin and 99.3% with leuprolide. The study reported equivalent maintenance rates later in treatment. | Early suppression differed in this trial; later maintenance was a separate outcome. |
| Hormone suppression alone predicts a child's adult height. | The pediatric study measured stimulated LH, sex steroids, and growth-related assessments during follow-up. Its primary endpoint was LH suppression at month six. | The hormone result is one part of care and does not determine an individual long-term outcome. |
Bottom line
Main takeaway
The depot injection releases medicine over time; its initial effect differs from its sustained effect.
The clinician selects the product for the diagnosis and monitors hormone response and safety.
The adult randomized trial measured testosterone suppression; the pediatric single-arm study measured stimulated LH suppression.
Identity
What it is
Triptorelin is a synthetic ten-amino-acid GnRH analog. The referenced U.S. products are extended-release suspensions administered by intramuscular injection.
Trelstar is labeled for advanced prostate cancer. Triptodur is labeled for central precocious puberty in children aged two years and older.
Use context
Routes, doses, and cycle patterns
The product strength and indication determine the interval between injections. Each product is administered by a healthcare professional.
Human studies and product labels
Trelstar for advanced prostate cancer
- Purpose
- Treatment of advanced prostate cancer
- Context
- U.S. adult product label
- Route
- Intramuscular injection
- Amount
- 3.75 mg, 11.25 mg, or 22.5 mg, depending on the selected strength
- Frequency
- Every four, 12, or 24 weeks, respectively
- Duration
- Determined by the cancer treatment plan
The label states that the strengths are not additive because their release characteristics differ.
Triptodur for central precocious puberty
- Purpose
- Treatment of central precocious puberty in children aged two years and older
- Context
- U.S. pediatric product label
- Route
- Intramuscular injection
- Amount
- 22.5 mg
- Frequency
- Every 24 weeks
- Duration
- Determined by the pediatric clinician according to the timing of puberty
The label describes hormone monitoring beginning one to two months after treatment starts, as needed during treatment, and with each subsequent dose, height measurement every three to six months, and periodic bone-age assessment.
Monthly prostate cancer comparison
- Purpose
- Compare testosterone suppression in advanced prostate cancer
- Context
- Randomized trial of triptorelin and leuprolide
- Route
- Intramuscular injection
- Amount
- Triptorelin 3.75 mg compared with leuprolide 7.5 mg
- Frequency
- Every 28 days for nine injections
- Duration
- Nine months of study treatment
The trial measured both early suppression and maintenance of the testosterone threshold.
What varies
- Trelstar's three strengths have distinct release schedules and are not additive.
- The Trelstar label calls for monitoring testosterone after injection and periodic checks of blood lipids and blood glucose or HbA1c.
- Triptodur's label calls for hormone monitoring beginning one to two months after treatment starts, as needed during treatment, and with each subsequent dose, along with height and bone-age assessments.
Research
Research evidence
A randomized study compared monthly triptorelin with leuprolide in advanced prostate cancer. A separate single-arm study assessed a 24-week formulation in children with central precocious puberty. The studies used different populations and hormone endpoints.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Triptorelin versus leuprolide | 284 men with advanced prostate cancer | Randomized comparative trial | Monthly intramuscular triptorelin or leuprolide | Testosterone suppression at day 29 was reported in 91.2% of the triptorelin group and 99.3% of the leuprolide group; the study reported equivalent maintenance rates later. | The hormone threshold does not by itself establish long-term cancer outcomes for an individual. | Controlled human study |
| Six-month triptorelin in central precocious puberty | 44 previously untreated children with central precocious puberty | Multicenter, single-arm phase 3 study | Two 22.5 mg intramuscular injections, 24 weeks apart | Forty-one children reached the study's stimulated LH threshold at month six and maintained suppression through month 12; 43 of 44 met the threshold at month 12. | The study had no randomized comparator and followed the primary study outcomes for one year. | Single-arm human study |
Cautions
Safety and unknowns
- Trelstar can initially raise testosterone and temporarily worsen prostate cancer symptoms. The label calls for close monitoring when spinal metastases or urinary obstruction are present.
- The Trelstar label describes metabolic changes, including hyperglycemia, and reports of cardiovascular events in men receiving GnRH agonists.
- The Trelstar label also warns about seizures, severe skin reactions, and possible QT interval prolongation. It advises clinicians to consider periodic electrocardiograms and electrolyte monitoring, particularly when relevant heart conditions, electrolyte abnormalities, or other QT-prolonging medicines are present.
- Triptodur's pediatric warnings include psychiatric symptoms, seizures, severe skin reactions, and increased pressure around the brain. Headache or visual changes should be discussed promptly with the treating clinician.
- The Triptodur label lists pregnancy and specified hypersensitivities as contraindications. Trelstar also warns about fetal harm and contraindicates specified hypersensitivity.
Product quality
Product identity and quality
Both products are supplied as powders for preparation and intramuscular administration by a healthcare professional.
Product and strength
The prostate cancer and pediatric products have separate labels, and Trelstar strengths have different release characteristics.
Preparation
Each label specifies preparation and administration instructions for its depot suspension.
Mechanism
How it is proposed to work
With sustained treatment, triptorelin reduces pituitary signals that drive sex hormone production.
An initial stimulatory phase can briefly raise LH, follicle-stimulating hormone (FSH), and sex hormones before sustained suppression.
The clinical purpose differs between prostate cancer treatment and central precocious puberty.
FAQ
Common questions
What is the difference between Trelstar and Triptodur?
Trelstar is labeled for advanced prostate cancer, while Triptodur is labeled for central precocious puberty in children two years and older. Each product has its own instructions.
Can Trelstar depot strengths be added together?
The Trelstar label says its strengths are not additive because their release characteristics differ.
What monitoring does the Triptodur label describe?
The label calls for hormone monitoring beginning one to two months after treatment starts, as needed during treatment, and with each subsequent dose, height measurement every three to six months, and periodic bone-age assessment.
Details
Technical details
Sources
References
- 1.
DailyMed. Trelstar triptorelin pamoate prescribing information
U.S. label for Trelstar strengths and schedules in advanced prostate cancer.
- 2.
DailyMed. Triptodur triptorelin extended-release prescribing information
U.S. label for the pediatric central precocious puberty formulation.
- 3.
PubMed. Randomized comparison of triptorelin and leuprolide in advanced prostate cancer
doi:10.1046/j.1464-410x.2003.04308.x PMID:12887472
Trial comparing monthly triptorelin and leuprolide for testosterone suppression.
- 4.
PubMed. Triptorelin six-month formulation in central precocious puberty
doi:10.1515/jpem-2015-0376 PMID:26887034
Single-arm phase 3 study of two injections in children with central precocious puberty.